Logo

BeiGene’s Blincyto (blinatumomab) Receives the NMPA’s Approval for Pediatric Patients with Relapsed or Refractory B-Cell Precursor ALL

Share this
BeiGene’s Blincyto (blinatumomab) Receives the NMPA’s Approval for Pediatric Patients with Relapsed or Refractory B-Cell Precursor ALL

BeiGene’s Blincyto (blinatumomab) Receives the NMPA’s Approval for Pediatric Patients with Relapsed or Refractory B-Cell Precursor ALL

Shots:

  • NMPA has granted conditional approval of Blincyto (blinatumomab) for injection for the treatment of pediatric patients with r/r CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL)
  • This approval is based on ex-China research data and Chinese adult data. The full approval in this indication will be based on the results of a post-marketing study in China
  • This approval marked the second approval for the therapy in China. Blincyto is a BiTE (bispecific T-cell engager) immuno-oncology therapy that targets CD19 surface antigens on B cells

Ref: BeiGene | Image: BeiGene

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions